$CADL
Candel Therapeutics, Inc. Stock $cadl

$cadl Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000095017022004857 Filed on March 29, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021
Revenue	$31.00K	$31.00K	$125.0K
YoY Change	0.0%	0.0%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.600M	$3.917M	$10.67M
YoY Change	86.05%	49.39%	106.0%
% of Gross Profit
Research & Development	$5.417M	$3.854M	$15.18M
YoY Change	96.77%	9.18%	73.38%
% of Gross Profit
Depreciation & Amortization	$165.0K	$178.0K	$232.0K
YoY Change	534.62%	2866.67%	154.95%
% of Gross Profit
Operating Expenses	$9.017M	$7.771M	$25.85M
YoY Change	92.34%	26.23%	85.51%
Operating Profit	-$8.986M		-$25.73M
YoY Change	92.96%		86.29%
Interest Expense	-$175.0K	-$11.00K	-$53.00K
YoY Change	1358.33%	-122.45%	-147.75%
% of Operating Profit
Other Income/Expense, Net	$8.112M	$9.347M	-$10.40M
YoY Change	4431.84%	-312.34%	168.68%
Pretax Income	-$874.0K	$1.596M	-$36.12M
YoY Change	-80.48%	-115.23%	104.32%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$874.0K	$1.596M	-$36.12M
YoY Change	-80.48%	-115.23%	104.32%
Net Earnings / Revenue	-2819.35%	5148.39%	-28899.2%
Basic Earnings Per Share	-$0.03		-$1.91
Diluted Earnings Per Share	-$30.46K	$55.50K	-$1.914M
COMMON SHARES
Basic Shares Outstanding	28.69M	28.69M	18.87M
Diluted Shares Outstanding	28.69M		18.87M

Balance Sheet

Concept	2022 Q1	2021 Q4	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$94.32M	$82.64M	$82.64M
YoY Change	223.55%		135.76%
Cash & Equivalents	$94.32M	$82.64M	$82.64M
Short-Term Investments
Other Short-Term Assets	$1.325M	$2.303M	$2.303M
YoY Change	315.36%		2376.34%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$95.65M	$84.95M	$84.95M
YoY Change	224.54%	141.69%	141.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.264M	$3.836M	$3.836M
YoY Change	0.02%	37.64%	37.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$437.0K	$424.0K	$424.0K
YoY Change	-67.87%	21.49%	21.49%
Total Long-Term Assets	$5.916M	$4.260M	$4.260M
YoY Change	5.21%	35.84%	35.84%
TOTAL ASSETS
Total Short-Term Assets	$95.65M	$84.95M	$84.95M
Total Long-Term Assets	$5.916M	$4.260M	$4.260M
Total Assets	$101.6M	$89.21M	$89.21M
YoY Change	189.4%	133.02%	133.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.386M	$1.590M	$1.590M
YoY Change	-8.39%	72.64%	72.64%
Accrued Expenses	$3.563M	$3.438M	$3.438M
YoY Change	8.04%	9.42%	9.42%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.472M	$5.362M	$5.362M
YoY Change	-0.47%	13.77%	13.77%
LONG-TERM LIABILITIES
Long-Term Debt	$20.53M	$560.0K	$560.0K
YoY Change	3988.65%		15.94%
Other Long-Term Liabilities	$11.80M	$19.15M	$19.15M
YoY Change	56.73%		152.32%
Total Long-Term Liabilities	$32.33M	$19.71M	$19.71M
YoY Change	302.44%		144.16%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.472M	$5.362M	$5.362M
Total Long-Term Liabilities	$32.33M	$19.71M	$19.71M
Total Liabilities	$37.80M	$25.07M	$25.07M
YoY Change	179.36%	96.09%	96.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$81.17M	-$80.30M
YoY Change		81.78%
Common Stock	$144.9M	$144.4M
YoY Change		600.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$63.76M	$64.14M	$64.14M
YoY Change
Total Liabilities & Shareholders Equity	$101.6M	$89.21M	$89.21M
YoY Change	189.4%	133.02%	133.02%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021
OPERATING ACTIVITIES
Net Income	-$874.0K	$1.596M	-$36.12M
YoY Change	-80.48%	-115.23%	104.32%
Depreciation, Depletion And Amortization	$165.0K	$178.0K	$232.0K
YoY Change	534.62%	2866.67%	154.95%
Cash From Operating Activities	-$8.053M	-$5.238M	-$22.22M
YoY Change	43.11%	53.34%	144.93%
INVESTING ACTIVITIES
Capital Expenditures	$171.0K	-$504.0K	$1.835M
YoY Change	-25.33%	11.26%	24.32%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities	-$171.0K	-$504.0K	-$1.835M
YoY Change	-25.33%	-102.5%	-104.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	19.92M	0.000	71.80M
YoY Change	17682.14%	-100.0%	14553.06%
NET CHANGE
Cash From Operating Activities	-8.053M	-5.238M	-22.22M
Cash From Investing Activities	-171.0K	-504.0K	-1.835M
Cash From Financing Activities	19.92M	0.000	71.80M
Net Change In Cash	11.69M	-5.742M	47.75M
YoY Change	-303.55%	-134.19%	59.83%
FREE CASH FLOW
Cash From Operating Activities	-$8.053M	-$5.238M	-$22.22M
Capital Expenditures	$171.0K	-$504.0K	$1.835M
Free Cash Flow	-$8.224M	-$4.734M	-$24.05M
YoY Change	40.44%	59.77%	128.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	dei	Entity File Number EntityFileNumber	001-40629
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P7Y
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.407
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001841387
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Entity Registrant Name EntityRegistrantName	CANDEL THERAPEUTICS, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	52-2214851
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	117 Kendrick St
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 450
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Needham
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02494
CY2021	dei	City Area Code CityAreaCode	617
CY2021	dei	Local Phone Number LocalPhoneNumber	916-5445
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2021	dei	Trading Symbol TradingSymbol	CADL
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	334000
CY2021	dei	Auditor Location AuditorLocation	McLean, Virginia
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82642000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35053000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2303000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	93000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	921000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3438000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3142000
CY2020Q4	cadl	Paycheck Protection Program Loan Current PaycheckProtectionProgramLoanCurrent	463000
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	106500000
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28691088
CY2021	dei	Auditor Firm AuditorFirmId	185
CY2021	dei	Auditor Name AuditorName	KPMG LLP
CY2021Q4	us-gaap	Assets Current AssetsCurrent	84945000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	35146000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3836000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2787000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	424000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	349000
CY2021Q4	us-gaap	Assets Assets	89205000
CY2020Q4	us-gaap	Assets Assets	38282000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1590000
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	187000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5362000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4713000
CY2020Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	125000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	560000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	483000
CY2021Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	894000
CY2020Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	632000
CY2021Q4	cadl	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	18252000
CY2020Q4	cadl	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	6831000
CY2021Q4	us-gaap	Liabilities Liabilities	25068000
CY2020Q4	us-gaap	Liabilities Liabilities	12784000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28689842
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28689842
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11635094
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11635094
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	286000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	116000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	144146000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	20493000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-80295000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-44171000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	64137000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-23562000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89205000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38282000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	125000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	125000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15178000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8754000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10673000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5181000
CY2021	us-gaap	Operating Expenses OperatingExpenses	25851000
CY2020	us-gaap	Operating Expenses OperatingExpenses	13935000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-25726000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-13810000
CY2021	us-gaap	Nonoperating Gains Losses NonoperatingGainsLosses	1076000
CY2020	us-gaap	Nonoperating Gains Losses NonoperatingGainsLosses	624000
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	-53000
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	111000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	11421000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4605000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10398000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3870000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-36124000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-17680000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	19000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36124000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17661000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.91
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.52
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18873048
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11615208
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-8038000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1412000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	695000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	19000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-17680000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-23562000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	35000
CY2021	cadl	Stock Issued During Period Value Warrant Exercised StockIssuedDuringPeriodValueWarrantExercised	430000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2588000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	375000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	2107000
CY2021	cadl	Non Cash Interest Expense NonCashInterestExpense	76000
CY2020	cadl	Non Cash Interest Expense NonCashInterestExpense	32000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	11421000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	39937000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	71335000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-36124000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	64137000
CY2021	us-gaap	Profit Loss ProfitLoss	-36124000
CY2020	us-gaap	Profit Loss ProfitLoss	-17680000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	232000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	91000
CY2021	cadl	Impairment On Manufacturing Equipment ImpairmentOnManufacturingEquipment	553000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2963000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4605000
CY2021	cadl	Paycheck Protection Program Loan Forgiveness PaycheckProtectionProgramLoanForgiveness	463000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2210000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-60000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-83000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	83000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	669000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	289000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	297000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1512000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-125000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-125000
CY2021	cadl	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	410000
CY2020	cadl	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	121000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22218000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9071000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	6000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1835000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1476000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1835000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	38455000
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	71335000
CY2020	cadl	Proceeds From Paycheck Protection Program Loan ProceedsFromPaycheckProtectionProgramLoan	460000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	430000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	35000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	71800000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	490000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	47747000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	29874000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35319000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5445000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	266000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-80295000
CY2021Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one-for-2.4579
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83066000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35319000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	29000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	93000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	977000
CY2021	cadl	Number Of Product Candidates NumberOfProductCandidates	2
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-36124000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-17680000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2921000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	352000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Arial;font-style:italic;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates, which include but are not limited to management’s judgments of accrued expenses, valuation of share-based awards, valuations of warrants, fair value of debt and income taxes. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;">Prior to the IPO, the Company utilized significant estimates and assumptions in determining the fair value of its common stock. The Company has utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its common stock and warrants. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date.</span>
CY2021	cadl	Cash And Cash Equivalent Maturity Period CashAndCashEquivalentMaturityPeriod	P90D
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	424000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	134000
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Arial;font-style:italic;">Concentrations of credit risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. Periodically, the Company maintains deposits and investments in accredited financial institutions in-excess of the federally insured limits. The Company deposits its cash in financial institutions with a high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal risk associated with commercial banking relationships.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;"> </span></p>
CY2021Q4	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	553000
CY2021	cadl	Expected Dividend Assumed ExpectedDividendAssumed	0
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3836000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2787000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	232000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	91000
CY2021	cadl	Percentage Income Taxes Benefits Upon Ultimate Settlement PercentageIncomeTaxesBenefitsUponUltimateSettlement	0.50
CY2021Q4	cadl	Expected Operating Lease Right Of Use Asset ExpectedOperatingLeaseRightOfUseAsset	1300000
CY2021Q4	cadl	Expected Operating Lease Liability ExpectedOperatingLeaseLiability	2400000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4188000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28689842
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28689842
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11635094
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11635094
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.84
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y2M4D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	12272000
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	2731222
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	2.72
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2096000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1198000
CY2021Q4	cadl	Accrued Third Party Research And Development Expenses Current AccruedThirdPartyResearchAndDevelopmentExpensesCurrent	632000
CY2020Q4	cadl	Accrued Third Party Research And Development Expenses Current AccruedThirdPartyResearchAndDevelopmentExpensesCurrent	1299000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	710000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	645000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3438000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3142000
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	17187676
CY2021	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	7066398
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	14170038
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	18725659
CY2021Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one-for-2.4579
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1878997
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	928286
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.43
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y6M3D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	120000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3221378
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.55
CY2020	cadl	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P3Y9M29D
CY2020	cadl	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue	10997000
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	21359
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.46
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	114994
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	1.46
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4013311
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.52
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y5M12D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	13818000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	808711
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.34
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.46
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	14279
CY2021	cadl	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P9Y4M2D
CY2021	cadl	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue	1194000
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	24410
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	1.55
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4783333
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.34
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M3D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	26393000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2052111
CY2021	cadl	Sharebased Compensation Arrangement By Sharebased Payment Award Options Unvested Weighted Average Remaining Contractual SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractual	P8Y9M3D
CY2021Q4	cadl	Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedIntrinsicValue	14121000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	6648000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	12000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2963000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2107000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	6298000
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	4778000
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M3D
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y18D
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	cadl	Effective Income Tax Rate Reconciliation Permanent Adjustments EffectiveIncomeTaxRateReconciliationPermanentAdjustments	-0.0059
CY2020	cadl	Effective Income Tax Rate Reconciliation Permanent Adjustments EffectiveIncomeTaxRateReconciliationPermanentAdjustments	-0.0107
CY2021	cadl	Effective Income Tax Rate Reconciliation Mark To Market EffectiveIncomeTaxRateReconciliationMarkToMarket	0.0664
CY2020	cadl	Effective Income Tax Rate Reconciliation Mark To Market EffectiveIncomeTaxRateReconciliationMarkToMarket	0.0547
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0401
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0665
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.1986
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2395
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0208
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0284
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13892000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7934000
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	654000
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	750000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	243000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	346000
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	34000
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	68000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	820000
CY2020	cadl	Deferred Tax Assets Valuation Allowance Increase Recorded To Income Tax Provision DeferredTaxAssetsValuationAllowanceIncreaseRecordedToIncomeTaxProvision	4248000
CY2020	cadl	Deferred Tax Assets Valuation Allowance Decrease Recorded To Income Tax Provision DeferredTaxAssetsValuationAllowanceDecreaseRecordedToIncomeTaxProvision	19000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18493000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	431000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2850000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1789000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18493000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11318000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18493000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11318000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11318000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7089000
CY2021	cadl	Deferred Tax Assets Valuation Allowance Increase Recorded To Income Tax Provision DeferredTaxAssetsValuationAllowanceIncreaseRecordedToIncomeTaxProvision	7175000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11318000
CY2021	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	The federal and state tax returns are generally subject to examination for the years ended December 31, 2014 through December 31, 2021. There are currently no pending tax examinations.
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	125000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	125000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	459000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	619000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	567000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	583000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	598000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	613000
CY2021Q4	cadl	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	415000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2776000
CY2021	cadl	Noncancelable Operating Lease Expiration Date NoncancelableOperatingLeaseExpirationDate	2026
CY2021	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	0
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-36124000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-17680000
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18873048
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11615208
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.91
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.52
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12291041
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18638617
CY2022Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	5000000.0
CY2022Q4	cadl	Cash Proceeds Amount Equal To At Least From The Issuance And Sale Of Equity Securities CashProceedsAmountEqualToAtLeastFromTheIssuanceAndSaleOfEquitySecurities	75000000.0

Files In Submission

Name	View Source	Status
0000950170-22-004857-index-headers.html	Edgar Link	pending
0000950170-22-004857-index.html	Edgar Link	pending
0000950170-22-004857.txt	Edgar Link	pending
0000950170-22-004857-xbrl.zip	Edgar Link	pending
cadl-20211231.htm	Edgar Link	pending
cadl-20211231.xsd	Edgar Link	pending
cadl-20211231_cal.xml	Edgar Link	unprocessable
cadl-20211231_def.xml	Edgar Link	unprocessable
cadl-20211231_htm.xml	Edgar Link	completed
cadl-20211231_lab.xml	Edgar Link	unprocessable
cadl-20211231_pre.xml	Edgar Link	unprocessable
cadl-ex10_11.htm	Edgar Link	pending
cadl-ex10_12.htm	Edgar Link	pending
cadl-ex10_13.htm	Edgar Link	pending
cadl-ex21_1.htm	Edgar Link	pending
cadl-ex23_1.htm	Edgar Link	pending
cadl-ex31_1.htm	Edgar Link	pending
cadl-ex31_2.htm	Edgar Link	pending
cadl-ex32.htm	Edgar Link	pending
cadl-ex4_2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img211153731_0.jpg	Edgar Link	pending
img211153731_1.jpg	Edgar Link	pending
img211153731_10.jpg	Edgar Link	pending
img211153731_11.jpg	Edgar Link	pending
img211153731_12.jpg	Edgar Link	pending
img211153731_13.jpg	Edgar Link	pending
img211153731_14.jpg	Edgar Link	pending
img211153731_15.jpg	Edgar Link	pending
img211153731_16.jpg	Edgar Link	pending
img211153731_17.jpg	Edgar Link	pending
img211153731_18.jpg	Edgar Link	pending
img211153731_19.jpg	Edgar Link	pending
img211153731_2.jpg	Edgar Link	pending
img211153731_20.jpg	Edgar Link	pending
img211153731_21.jpg	Edgar Link	pending
img211153731_22.jpg	Edgar Link	pending
img211153731_23.jpg	Edgar Link	pending
img211153731_24.jpg	Edgar Link	pending
img211153731_25.jpg	Edgar Link	pending
img211153731_26.jpg	Edgar Link	pending
img211153731_3.jpg	Edgar Link	pending
img211153731_4.jpg	Edgar Link	pending
img211153731_5.jpg	Edgar Link	pending
img211153731_6.jpg	Edgar Link	pending
img211153731_7.jpg	Edgar Link	pending
img211153731_8.jpg	Edgar Link	pending
img211153731_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CADL
Candel Therapeutics, Inc. Stock $cadl

2022 Q1 Form 10-K Financial Statement

#000095017022004857 Filed on March 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CADL Candel Therapeutics, Inc. Stock $cadl

2022 Q1 Form 10-K Financial Statement

#000095017022004857 Filed on March 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CADL
Candel Therapeutics, Inc. Stock $cadl